Pharmaceuticals, Biotechnology and Life Sciences
IMV is preparing to advance a DPX-based vaccine candidate for COVID-19, which is on track to enter into clinical trials later this summer.
CanFite is working on Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the…
Avacta said that Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.
Abivax said Thursday that ABX464 inhibits replication of SARS-CoV-2 in an in vitro reconstituted human respiratory epithelium model, as assessed by Transepithelial electrical resistance and RTqPCR.
Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice.
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
DENVER–(BUSINESS WIRE)–ClinOne is expanding its strategic collaboration with BioIntelliSense to combine continuous health monitoring and clinical intelligence with the ClinOne…
Cooley lawyers working in the technology and life sciences industries have been advising some of the world’s most innovative companies as they seek to deliver products and services to battle myriad aspects of the COVID-19 pandemic.
Industry leaders connecting patient advocacy organizations in virtual approach ROCHESTER, N.Y. & PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #AdvocacyExchange–In light of the COVID-19…
Novavax said Monday that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2.